| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.AMJCARD.2007.11.023 |
| P698 | PubMed publication ID | 18328855 |
| P50 | author | Henry Krum | Q82083581 |
| P2093 | author name string | Baki Billah | |
| Genevieve Flannery | |||
| Rosie Gehrig-Mills | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| patient | Q181600 | ||
| systole | Q496359 | ||
| chronic heart failure | Q11829287 | ||
| P304 | page(s) | 865-869 | |
| P577 | publication date | 2008-02-21 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | American Journal of Cardiology | Q2208417 |
| P1476 | title | Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers | |
| P478 | volume | 101 |
| Q28068618 | A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure |
| Q88536384 | Adding ivabradine to beta-blockers in chronic heart failure: Do not rest without lowering the resting heart rate sufficiently |
| Q89891134 | Association of pulse rate with outcomes in heart failure with reduced ejection fraction: a retrospective cohort study |
| Q48818918 | Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction. |
| Q90578720 | Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. |
| Q88723395 | Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy |
| Q38170307 | Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. |
| Q90466333 | Cardiogenic shock induced by bisoprolol in a patient with CYP2D6 variant. A case report |
| Q85886912 | Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure |
| Q50064555 | Chronic obstructive pulmonary disease and β-blocker treatment in Asian patients with heart failure |
| Q86450989 | Clinical significance of heart rate during acute decompensated heart failure to predict left ventricular reverse remodeling and prognosis in response to therapies in nonischemic dilated cardiomyopathy |
| Q91866363 | Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction |
| Q38737757 | Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure |
| Q28083086 | Drug therapy for heart failure in older patients-what do they want? |
| Q37121912 | Echocardiographic assessment of pressure volume relations in heart failure and valvular heart disease: using imaging to understand physiology. |
| Q48628883 | Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial) |
| Q90324698 | Effects of Ivabradine on Hemodynamic and Functional Parameters in Left Ventricular Systolic Dysfunction: a Systematic Review and Meta-analysis |
| Q43285131 | Effects of selective I f-channel inhibition with ivabradine on hemodynamics in a patient with restrictive cardiomyopathy |
| Q64271269 | Genetics of heart rate in heart failure patients (GenHRate) |
| Q52686636 | Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β-Blockers |
| Q91458170 | Heart failure treatment and the art of medical decision making |
| Q42923271 | Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial |
| Q37497745 | Heart rate as a treatable cardiovascular risk factor |
| Q33902610 | Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine |
| Q83607786 | Heart rate decrease: A new paradigm in the treatment of heart failure. Insights from the SHIFT study |
| Q56958327 | Heart rate following short-term beta-blocker titration predicts all-cause mortality in elderly chronic heart failure patients: insights from the CIBIS-ELD trial |
| Q88536437 | Heart rate manipulation in dilated cardiomyopathy: Assessing the role of Ivabradine |
| Q38042855 | Heart rate reduction in heart failure: ivabradine or beta blockers? |
| Q38127568 | Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties |
| Q50477045 | Home-measured heart rate is associated with albuminuria in patients with type 2 diabetes mellitus: a post-hoc analysis of a cross-sectional multicenter study. |
| Q38140796 | How does renal denervation lower blood pressure and when should this technique be considered for the treatment of hypertension? |
| Q37798963 | If Inhibition in Cardiovascular Diseases |
| Q55309021 | Impact of Heart Rate Reduction with Maximal Tolerable Dose of Bisoprolol on Left Ventricular Reverse Remodeling. |
| Q52670398 | Importance of Baseline Heart Rate as a Predictor of Cardiac Functional Recovery in Newly Diagnosed Heart Failure with Reduced Ejection Fraction. |
| Q37857335 | Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine |
| Q42226118 | Is heart rate reduction more important than target dose in chronic heart failure therapy with a beta-blocker? |
| Q43876179 | Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure? |
| Q28291971 | Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study |
| Q38769814 | Ivabradine for the treatment of chronic heart failure |
| Q38546740 | Ivabradine in Management of Heart Failure: a Critical Appraisal |
| Q34253493 | Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice |
| Q26865770 | Ivabradine, coronary artery disease, and heart failure: beyond rhythm control |
| Q38797276 | Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction |
| Q35544382 | Nemaline myopathy and heart failure: role of ivabradine; a case report |
| Q53637670 | Pathophysiologic Insights into Heart Rate Reduction in Heart Failure: Implications in the Use of Beta-Blockers and Ivabradine |
| Q37798181 | Pharmacologic modulation of parasympathetic activity in heart failure |
| Q38859866 | Phase 4 Studies in Heart Failure - What is Done and What is Needed? |
| Q39317320 | Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management |
| Q88747990 | Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF |
| Q43247698 | Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). |
| Q46239241 | Reduced intrinsic heart rate is associated with reduced arrhythmic susceptibility in guinea-pig heart |
| Q39248876 | Resting Heart Rate and Ischemic Stroke in Patients with Heart Failure |
| Q37233293 | Resting heart rate and outcomes in patients with cardiovascular disease: where do we currently stand? |
| Q98213781 | Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with beta-blockers |
| Q34089856 | Resting heart rate is a risk factor for mortality in chronic obstructive pulmonary disease, but not for exacerbations or pneumonia |
| Q38751093 | Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease. |
| Q37986643 | Role of heart rate as a marker and mediator of poor outcome for patients with heart failure |
| Q83554944 | Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertension |
| Q37923966 | Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease |
| Q83622758 | The beat goes on: on the importance of heart rate in chronic heart failure |
| Q88451108 | The effects of heart rate control in chronic heart failure with reduced ejection fraction |
| Q53621468 | The effects of ivabradine on left atrial electromechanical function in patients with systolic heart failure |
| Q44694136 | The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. |
| Q58568726 | The therapeutic role of ivabradine in heart failure |
| Q98291427 | β-Blocker Doses and Heart Rate in Patients with Heart Failure: Results from the National Norwegian Heart Failure Registry |
| Q37822723 | β-blockers and their mortality benefits: underprescribed in heart failure and chronic obstructive pulmonary disease |
Search more.